American Journal of Case Reportsに掲載された記事は、新型コロナウイルス感染症患者に対する維持光生体調節療法の可能性を実証しています。.
ローウェル, マ, 8月. 9, 2020 /PRNewswire/ — 主任研究者および主著者である博士. スコット・シグマン医師は本日、新型コロナウイルス肺炎患者の治療に初めてレーザー治療を使用した結果、肯定的な結果が得られたと報告した。. American Journal of Case Reportsに掲載された記事では、光生体調節療法による支持療法後に、 (PBMT), 患者の呼吸指数, X線検査所見, 酸素要求量, 人工呼吸器を必要とせずに数日以内に転帰が改善. 1 この報告書に含まれる患者は、以下のランダム化臨床試験に参加した。 10 新型コロナウイルス感染症が確認された患者.
患者さん, SARS-CoV-2と診断された57歳のアフリカ系アメリカ人, 呼吸窮迫症候群で集中治療室に入院し、酸素が必要だった. 彼は、FDA 承認のマルチウェーブ ロッキング システムを使用した 28 分間の PBMT セッションを毎日 4 回受けました。 (MLS) レーザー治療装置 (ASAレーザー, イタリア). この研究で使用されたMLS治療レーザーは、ロチェスターのCutting Edge Laser Technologiesによって北米のみで販売されています。, ニューヨーク. PBMT に対する患者の反応は、レーザー治療の前後でさまざまな評価ツールを比較することによって評価されました。, 治療後にはすべて改善されました. 結果は次のことを示しています:
治療前, 患者は激しい咳のため寝たきりで動くこともできなかった. 治療後, 患者の咳の症状は消えた, そして彼は理学療法の訓練の助けを借りて地上に降りることができた. The next day he was discharged to a rehabilitation center on minimal oxygen support. After only one day, the patient was able to complete two trials of stair climbing with physiotherapy and was transferred to room air. At follow-up, his clinical recovery lasted a total of three weeks, with the median time typically being six to eight weeks.
“Additional photobiomodulation therapy has proven effective in treating respiratory symptoms in severe cases of pneumonia caused by COVID-19. We believe this treatment option is a viable maintenance option,” 博士. Sigman said. “There is an ongoing medical need for safer and more effective treatment options for COVID-19. We hope that this report and subsequent studies will encourage others to consider additional clinical trials using adjuvant PBMT for the treatment of COVID-19 pneumonia.”
In PBMT, light is illuminated by damaged tissue and the light energy is absorbed by the cells, which initiates a series of molecular reactions that improve cellular function and speed up the body’s healing process. PBMT has proven anti-inflammatory properties and is emerging as an alternative method for pain relief, treatment of lymphedema, wound healing and musculoskeletal injuries. The use of maintenance PBMT to treat COVID-19 is based on the theory that laser light reaches lung tissue to reduce inflammation and promote healing. 加えて, PBMT is non-invasive, cost-effective, and has no known side effects.
The MLS laser uses a mobile scanner with 2 synchronized laser diodes, one pulsed (tunable from 1 に 2000 Hz) emitting at 905 nm and the other pulsed at 808 nm. Both laser wavelengths work simultaneously and are synchronized. The laser is placed 20 cm above the lying patient, across the lung field. Lasers are painless and patients are often unaware that laser treatment is taking place. This laser is often used on deeper tissues such as the hip and pelvic joints, which are surrounded by thick muscles. The therapeutic dose used to achieve deep pelvic targets was 4.5 J/cm2. Study co-author Dr. Soheila Mokmeli calculated that 7.2 J/cm2 was applied to the skin, delivering a therapeutic dose of laser energy of just over 0.01 J/cm2 to the lungs. This dose is able to penetrate the chest wall and reach the lung tissue, producing an anti-inflammatory effect that could theoretically block the effects of the cytokine storm in COVID-19 pneumonia. For more information about MLS laser treatment, please email Mark Mollenkopf [email protected] or call 800-889-4184 ext. 102.
For more information about this preliminary work and research program, please contact Scott A. Sigman, MD at [email protected] or call 978-856-7676.
1 Sigman S.A., Mokmeli S., Monich M., Vetrichi M.A. (2020). A 57-year-old African American man with severe COVID-19 pneumonia responds to supportive photobiomodulation therapy (PBMT): the first use of PBMT for COVID-19. Am J Case Rep 2020; 21:e926779. DOI: 10.12659/AJCR.926779
